TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05188677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty Vaccine
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxzevria Vaccine
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac Vaccine
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac Vaccine
Description: intramuscular injection
Study: NCT06329609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo 3 with respiratory rate algorithm
Description: Airvo 3 with respiratory rate algorithm is an active humidification system used to deliver high flow respiratory gases (air and/or oxygen) and monitor respiratory rate
Study: NCT06017050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BullyDown
Description: BullyDown is an 8 week, text messaging-based prevention program aimed to prevent bullying behaviors among middle school-aged youth. Message content is based upon the social-emotional learning model.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention-matched control
Description: The attention-matched control will receive the messages for the same number of days as the intervention. Content will talk about 'healthy lifestyle' topics, such as fitness and healthy social media use.
Study: NCT05886868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL0020
Description: Dose Escalation Stage: BL0020 will be administered via intravenous infusion on days 1 of a 21-days treatment cycle.~Dose Expansion Stage: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation Stage.
Study: NCT05446259

Intervention type: OTHER
Intervention: Standard clinical care procedures and outcome measurements.
Description: Standard of care surgical interventions, imaging impressions, laboratory results, and outcome measurements will be collected and analyzed.

Intervention type: OTHER
Intervention: Standard clinical care procedures and outcome measurements.
Description: Standard of care surgical interventions, imaging impressions, laboratory results, and outcome measurements will be collected and analyzed.
Study: NCT05489614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olpasiran
Description: Participants will receive olpasiran by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olpasiran
Description: Participants will receive olpasiran by subcutaneous (SC) injection.
Study: NCT04402294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The investigators will create individualized TMS targets using deep learning methods on task and resting fMRI data to target working memory augmentation. The individualized target will be stimulated in a subsequent fMRI scan involving working memory task performance interleaved with repetitive TMS (rTMS) delivered at a variety of stimulation frequencies. Based on activation readouts in response to rTMS, an optimal and sub-optimal brain state frequency to impact working memory performance will be selected for each participant. Participants will receive rTMS at each frequency separately for three days (six days total), with the order of frequency randomly assigned and counterbalanced. Following each three day protocol, another fMRI working memory readout will be conducted to support the targeting and frequency selection algorithms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The investigators will create individualized TMS targets using deep learning methods on task and resting fMRI data to target working memory augmentation. The individualized target will be stimulated in a subsequent fMRI scan involving working memory task performance interleaved with repetitive TMS (rTMS) delivered at a variety of stimulation frequencies. Based on activation readouts in response to rTMS, an optimal and sub-optimal brain state frequency to impact working memory performance will be selected for each participant. Participants will receive rTMS at each frequency separately for three days (six days total), with the order of frequency randomly assigned and counterbalanced. Following each three day protocol, another fMRI working memory readout will be conducted to support the targeting and frequency selection algorithms.
Study: NCT05053412

Intervention type: DIAGNOSTIC_TEST
Intervention: Helio Liver Test
Description: A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Helio Liver Test
Description: A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Helio Liver Test
Description: A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Helio Liver Test
Description: A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Helio Liver Test
Description: A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.
Study: NCT05796141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomy Support Training
Description: Participants will receive training in how to create an autonomy supportive environment within their marriage/partnership.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomy Support Training
Description: Participants will receive training in how to create an autonomy supportive environment within their marriage/partnership.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomy Support Training
Description: Participants will receive training in how to create an autonomy supportive environment within their marriage/partnership.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomy Support Training
Description: Participants will receive training in how to create an autonomy supportive environment within their marriage/partnership.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomy Support Training
Description: Participants will receive training in how to create an autonomy supportive environment within their marriage/partnership.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Environment Modifications
Description: Participants will be trained in how to structure their home environment to support health behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Environment Modifications
Description: Participants will be trained in how to structure their home environment to support health behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Environment Modifications
Description: Participants will be trained in how to structure their home environment to support health behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Environment Modifications
Description: Participants will be trained in how to structure their home environment to support health behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Environment Modifications
Description: Participants will be trained in how to structure their home environment to support health behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Environment Modifications
Description: Participants will be trained in how to structure their home environment to support health behavior.
Study: NCT05057000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercises + Diet
Description: Frequency 5-6 days per week Intensity To perform moderate intensity for weight-bearing aerobic exercise Time Goal of 20-30 min per session of moderate-intensity aerobic activity per week

Intervention type: OTHER
Group type: OTHER
Intervention: diet proram
Description: diet program for anorexic adolescent girls
Study: NCT06550466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast only
Description: Participants will attend a breakfast-only arm without the exercise protocol.
Study: NCT04193228

Intervention type: DEVICE
Intervention: Carbon Fibre Ankle Foot Orthosis
Description: Off teh shelf carbon fibre ankle foot orthoses worn bilaterally
Study: NCT05951387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: starting intravenous infusion with dexmedetomidine starting at dose 0.5ug/kg//hr and titrate the dose to achieve full sedation
Study: NCT04193228

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: Ankle muscle strength training
Study: NCT05326932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Description: Subjects in intervention group will receive MT as soon as possible. Investigators and clinicians should strive to reduce delays of pre-surgery procedure and follow the local standard guideline of MT during the operation and perioperative period. All CFDA approved devices are allowed in this trial. Angioplasty and stent placement can be performed at the discretion of the physicians. Base on site experience, the randomization-operation start period should be within 60 minutes.
Study: NCT04927611

Intervention type: PROCEDURE
Intervention: Biopsy, open or laparoscopic surgery
Description: Collect NEN and PDAC biopsy or surgical fresh tissue to conduct single cell sequencing or model construction.

Intervention type: PROCEDURE
Intervention: Biopsy, open or laparoscopic surgery
Description: Collect NEN and PDAC biopsy or surgical fresh tissue to conduct single cell sequencing or model construction.
Study: NCT05874700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium was given intravenously
Description: Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo was given intravenously
Description: Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
Study: NCT06550466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAST
Description: Participants will be exercised for 90 minutes following a 12-hour overnight fast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FED
Description: Participants will be exercised 90 minutes after a breakfast
Study: NCT06013748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-VOICES
Description: 7-10 individual VR assisted therapy for voice-hearing session and two booster sessions, in addition to TAU.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual as provided by the mental health centers
Study: NCT04816604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB002 (seralutinib)
Description: Capsule containing GB002 (seralutinib)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic Dry Powder Inhaler
Description: Generic dry powder inhaler for GB002 (seralutinib) delivery
Study: NCT06397508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGMB-129
Description: Each participant will receive 3 study interventions, 1 in each intervention period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGMB-129
Description: Each participant will receive 3 study interventions, 1 in each intervention period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGMB-129
Description: Each participant will receive 3 study interventions, 1 in each intervention period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGMB-129
Description: Each participant will receive 3 study interventions, 1 in each intervention period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGMB-129
Description: Each participant will receive 3 study interventions, 1 in each intervention period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGMB-129
Description: Each participant will receive 3 study interventions, 1 in each intervention period
Study: NCT05661266

Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
Study: NCT05796141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Environment Modifications
Description: Participants will be trained in how to structure their home environment to support health behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Environment Modifications
Description: Participants will be trained in how to structure their home environment to support health behavior.
Study: NCT05382403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jada® System
Description: This is a U.S. FDA-cleared device intended for treatment of PPH when conservative management is warranted. The device is made of medical grade silicone. The distal end, which is placed in the uterus, is an elliptical loop. The circular cervical seal, just outside the external cervical os, is filled with 60 - 120 mL sterile water. Low-level vacuum (80 ± 10 mm Hg) is applied and pooled blood is evacuated from the uterus as it collapses. Once there is no bleeding, the device remains in the uterus for at least 1 hour. The suction is then disconnected, the seal emptied of water, the device left in place, and the patient monitored for an additional 30 minutes. If bleeding remains controlled, the device is removed. If bleeding is uncontrolled with the Jada® System patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients in this group will receive care according to the treatment algorithm for PPH from uterine atony at the two teaching hospitals in Ghana. Possible interventions include additional uterotonics, tranexamic acid, and condom catheter balloon uterine tamponade. If bleeding is uncontrolled, patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
Study: NCT06161779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical reconstruction
Description: submental artery island flap (SMAIF) for the reconstruction of laryngeal and hypopharyngal defects after the surgical resection of hypopharyngeal cancer
Study: NCT05321615

Intervention type: DEVICE
Group type: OTHER
Intervention: Palpator
Description: Palpator for tumor localization

Intervention type: DEVICE
Group type: OTHER
Intervention: Grasper
Description: Atraumatic lung grasper

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: VATS ultrasound

Intervention type: OTHER
Group type: OTHER
Intervention: Finger palpation
Description: Palpation of the lung/tumour using the surgeon's finger
Study: NCT06412939

Intervention type: DEVICE
Intervention: Agile Nail
Description: Intramedullary implantation of the Agile intramedullary rigid nail in femur to provide bone fixation
Study: NCT05195723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WP1122
Description: Oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution
Study: NCT01740245

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine vaginal suppositories

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide vaginal suppositories
Study: NCT05018377

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Racz adhesolysis
Description: adhesiolysis in failed back surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NAVI adhesolysis
Description: adhesiolysis in failed back surgery
Study: NCT03763305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol continuous infusion
Description: Propofol intravenous continuous infusion for anesthetic induction and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil intravenous continuous infusion for anesthetic induction and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Study participants receive fentanyl 1mcg/kg and propofol 1.5\~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane is used to maintain 1 age-related minimum alveolar concentration (MAC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: 1 age-related minimum alveolar concentration (MAC) of desflurane inhalation for anesthetic maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol bolus injection
Description: Propofol intravenous injection for anesthetic induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol bolus injection
Description: Propofol intravenous injection for anesthetic induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl intravenous injection for anesthetic induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl intravenous injection for anesthetic induction
Study: NCT04833530

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric Ultrasound
Description: In the operating room, a gastric ultrasound will be performed in the supine position and the antral cross sectional area will be measured. Anesthesia will be induced in standard procedure and positive pressure will be instituted according to the standard protocol accepted in our hospital.~At the end of the procedure, the gastric ultrasound circumference will be measured again.
Study: NCT05965973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat diet
Description: During 3 days, subjects eat a diet low in fat (percent of total caloric intake: 15.0% from proteins; 65.0% from carbohydrates; 20.0% from fat: 4.0% from saturated fat; 10.0% from monounsaturated fat; 6.0% from polyunsaturated fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat diet
Description: During 3 days, subjects eat a diet low in fat (percent of total caloric intake: 15.0% from proteins; 65.0% from carbohydrates; 20.0% from fat: 4.0% from saturated fat; 10.0% from monounsaturated fat; 6.0% from polyunsaturated fat
Study: NCT05920473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS with Magstim Rapid 2 magnetic stimulation device
Description: The study will involve the utilization of the Magstim Rapid 2 magnetic stimulation device to administer rTMS treatment to the participants. The coil will be positioned tangentially on the scalp, specifically targeting the hot spot (thumb movement area) in the ipsilateral cerebral hemisphere. During the stimulation protocol, a 10-Hz stimulation will be applied for 2 seconds, followed by a 10-second rest period. This cycle will be repeated 50 times. The treatment will be administered once daily, from Monday to Friday, for a continuous period of two weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham control with Magstim Rapid 2 magnetic stimulation device
Description: In the sham group, patients received sham stimulation using the the Magstim Rapid 2 magnetic stimulation device with the same protocol. The coil was positioned to target the same hot spot, with an angulation parallel to the gyrus to further reduce the potential impact of rTMS.
Study: NCT05965973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat diet
Description: During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 45.0% from carbohydrates; 40.0% from fat: 8.0% from saturated fat; 22.0% from monounsaturated fat; 10.0% from polyunsaturated fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat diet
Description: During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 45.0% from carbohydrates; 40.0% from fat: 8.0% from saturated fat; 22.0% from monounsaturated fat; 10.0% from polyunsaturated fat
Study: NCT05071976

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICG-NIR angiography
Description: Capture NIR video of flap site beginning at time of ICG injection. At time of subjective peak intensity, capture video of flap and recipient wound bed. Measure rate of ICG egress from the global flap at 60, 120, and 180 seconds after initial dye injection from intraoperative video
Study: NCT05231005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Description: fourth dose of the BNT162b2 vaccine (30 microgram) adminstered IM
Study: NCT06623474

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnosed by traditional diagnostic markers（such as AFP or CT etc.）
Description: A prospective observational cohort study to explore the advantages of lipid metabolites as diagnostic markers for hepatocellular carcinoma compared to traditional diagnostic markers for hepatocellular carcinoma (e.g., AFP, enhanced CT, etc.).

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnosed by traditional diagnostic markers（such as AFP or CT etc.）
Description: A prospective observational cohort study to explore the advantages of lipid metabolites as diagnostic markers for hepatocellular carcinoma compared to traditional diagnostic markers for hepatocellular carcinoma (e.g., AFP, enhanced CT, etc.).
Study: NCT06626464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]MK-8189
Description: Oral administration
Study: NCT06625918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultraviolet B exposure to produce vitamin D synthesis
Description: Exposure using a UV skin care device on vitamin D production and immune response in healthy adults
Study: NCT06633367

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Increasing time in nature
Description: This intervention includes requesting an increase in time spent outdoors, eligibility to receive a prize, and information on peer performance.